Most CD3-targeted pan-T-cell stimulators at the clinical phase are designed to treat blood tumors, such as targeting CD19 and CD20 for non-Hodgkin lymphoma (NHL), targeting B cell maturation antigen (BCMA), GPRC5D and CD38 for multiple myeloma (MM), targeting CD33, CD123, and CLEC12A for acute myeloid leukemia (AML) (162). Here, TNFRSF17 is linked to plasma cell myeloma.